Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | TGM2 | P21980 | 9/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | F13A1 | P00488 | 6/20 | 0.45 |
| ▸ | TGM1 | P22735 | 3/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6958889 | 0.84 | GAA (0.47) | GAATGM2SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL20669117 | 0.82 | GAA (0.44) | GAATGM2SMN1; SMN2USP2 | |
| SCHEMBL7406478 | 0.81 | USP2 (0.53) | TGM2SMN1; SMN2USP2F13A1TGM1 | |
| SCHEMBL1487081 | 0.81 | USP2 (0.53) | TGM2SMN1; SMN2USP2F13A1TGM1 | |
| SCHEMBL56379 | 0.81 | USP2 (0.53) | TGM2SMN1; SMN2USP2L3MBTL1F13A1 | |
| SCHEMBL31616186 | 0.81 | GAA (0.42) | GAATGM2SMN1; SMN2USP2 | |
| SCHEMBL698803 | 0.80 | USP2 (0.69) | SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL18294 | 0.80 | USP2 (0.69) | SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL2249760 | 0.79 | USP2 (0.51) | GAATGM2SMN1; SMN2USP2L3MBTL1 | |
| SCHEMBL21981388 | 0.79 | GAA (0.41) | GAATGM2SMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780875-B2 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-24 | — | — | US | disclosed |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2003-11-13 | — | — | US | disclosed |
| EP-1131295-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031037-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNH2, KCNA6, KCNA3 | GAA 2857/4885TGM2 4523/4885SMN1; SMN2 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.